Lexicon post hoc SOLOIST-WHF analysis shows sotagliflozin benefit holds across baseline blood pressure levels
LXRX•Safety findings
Safety profile remained consistent across blood pressure strata, with no signal of higher hypotension or acute kidney injury versus placebo.
Commercial relevance
Data support broader use in clinically vulnerable heart failure patients, potentially expanding the addressable treatment population if commercialized.
Post hoc SOLOIST-WHF analysis
Lexicon Pharmaceuticals reported a post hoc analysis from the Phase 3 SOLOIST-WHF trial of sotagliflozin in worsening heart failure.
Results were presented at ESC Congress 2026 on Aug. 30, 2026, with simultaneous publication in JACC: Heart Failure.
Findings showed sotagliflozin benefits held across baseline systolic blood pressure levels, including patients starting with low readings.
